Increased positive predictive values for recall by 56 percentConclusion: The addition of tomosynthesis (3-D) to mammography in women 40 to 49 years old shows improved outcomes in recall rates and cancer detection rates (similar to the general population).Tomosynthesis (3-D) addresses a primary concern regarding screening women in their 40s by reducing recall rates as cited in both the USPSTF and the ACS guideline changes.Adding tomosynthesis (3-D) to mammography takes about the same amount of time as digital mammography yet takes around 60 pictures. Radiologists can now see cancers as early as stage zero with tomosynthesis.”Our study is confirming the benefits of tomosynthesis. For a disease with no known form of prevention, early detection is key and the earliest detection is with tomosynthesis, especially in women under 50 years old with dense beast tissue,” commented Dr. Rose.
“For years, radiologists and referring physicians have attested to the importance of early detection in saving lives and in offering women the best treatment options,” said James Polfreman, president and CEO, Solis Mammography. “Adding tomosynthesis to mammography represents the best technology available, offering more and clearer images of breast tissue, and less recalls, which in turn means less anxiety for the women we serve. Medicare began coverage for 3-D mammography in January 2015 and Cigna recently announced that it is now including 3-D mammography in their national coverage plans. This is an important milestone for women’s health, and we hope that with research like Dr. Rose’s, more private insurers will follow suit.”
Dr. Rose joined Solis Mammography as its chief medical officer in April of 2014. He is responsible for clinical quality, clinical research and leadership of Solis’ breast radiologists; serves as a spokesperson for the company regarding clinical quality; and plays a key role in the strategic growth of the company.
Dr. Rose is also the founder and president of Rose Imaging Specialists, P.A., the nation’s largest group of breast imaging specialists. He is a graduate of the Johns Hopkins University School of Medicine in Baltimore, Maryland. His residency in Diagnostic Radiology was completed at the University of Texas at Houston, including training at M.D. Anderson, Texas Children’s Hospital Memorial Hermann Health System and St. Joseph’s Hospital of Houston. He is a board-certified, nationally renowned breast radiologist and has dedicated his practice to the diagnosis of early breast cancer for almost two decades. Today he is considered one of the nation’s leading experts regarding tomosynthesis.
To download a copy of Dr. Rose’s abstract Tomosynthesis Impact on Screening Patients 40 to 491 go to: http://archive.rsna.org/2016/16015111.html.
About Solis Mammography
Celebrating 30 years in breast imaging, Solis Mammography is a specialized healthcare provider focused on delivering women an exceptional mammography experience. Headquartered in Addison, Texas, Solis currently operates 41 centers across six major markets – North Texas; Houston, Texas; Phoenix, Arizona; Columbus, Ohio; Greensboro, North Carolina, and through its recent acquisition of Washington Radiology Associates (WRA), the D.C. metropolitan area. The company operates both wholly-owned centers and multiple successful joint ventures with hospital partners. Solis Mammography (including WRA), serves more than 600,000 patients each year with highly-specialized imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy. For more information, visit www.SolisMammo.com, like on Facebook, follow on Pinterest, and subscribe to the YouTube channel.
1Abstract citation: Rose,S, Tomosynthesis Impact on Screening Patients 40 to 49. Radiological Society of North America 2016 Scientific Assembly and Annual Meeting, November 27 – December 2, 2016, Chicago IL. archive.rsna.org/2016/16015111.html Accessed November 23, 2016)